Vaccinex, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 42

Vaccinex, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Vaccinex, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Vaccinex, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vaccinex, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vaccinex, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vaccinex, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Vaccinex, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vaccinex, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vaccinex, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vaccinex, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vaccinex, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Vaccinex, Inc. Snapshot
Vaccinex, Inc. Overview
Key Information
Key Facts
Vaccinex, Inc. – Research and Development Overview
Key Therapeutic Areas
Vaccinex, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vaccinex, Inc. – Pipeline Products Glance
Vaccinex, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Vaccinex, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vaccinex, Inc. – Drug Profiles
BVX20
Product Description
Mechanism of Action
R&D Progress
VX15
Product Description
Mechanism of Action
R&D Progress
VX30
Product Description
Mechanism of Action
R&D Progress
VX35
Product Description
Mechanism of Action
R&D Progress
VX5
Product Description
Mechanism of Action
R&D Progress
VX70
Product Description
Mechanism of Action
R&D Progress
VX25
Product Description
Mechanism of Action
R&D Progress
VX45
Product Description
Mechanism of Action
R&D Progress
VX5
Product Description
Mechanism of Action
R&D Progress
Vaccinex, Inc. – Pipeline Analysis
Vaccinex, Inc. – Pipeline Products by Therapeutic Class
Vaccinex, Inc. - Pipeline Products By Target
Vaccinex, Inc. – Pipeline Products by Molecule Type
Vaccinex, Inc. – Recent Pipeline Updates
Vaccinex, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Vaccinex, Inc., Deals Volume Summary, 2004 to YTD 2011
Vaccinex, Inc., Deals Summary By Region, 2004 to YTD 2011
Vaccinex, Inc., Deals Summary, 2004 to YTD 2011
Vaccinex, Inc. Detailed Deal Summary
Venture Financing
Vaccinex Secures $25 Million In Series B Venture Financing Round
Vaccinex Raises $8.4 Million In Venture Financing
Equity Offering
Vaccinex Completes Private Placement Of $1 Million
Vaccinex Enters Into Co-Development Agreement With Teva Pharmaceutical Industries
Vaccinex Enters Into Research Collaboration With Schering
Biocon Enters Into A Strategic Partnership With Vaccinex
Vaccinex Enters Into Collaboration Agreement With Orphan Pharma International
Licensing Agreements
OPi Enters Into Licensing Agreement With Vaccinex
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Vaccinex, Inc. – Pipeline by Therapy Area and Indication, 2011
Vaccinex, Inc. – Pipeline by Stage of Development, 2011
Vaccinex, Inc. – Monotherapy Products in Pipeline, 2011
Vaccinex, Inc. - Phase I, 2011
Vaccinex, Inc. - Pipeline By Therapeutic Class, 2011
Vaccinex, Inc. - Pipeline By Target, 2011
Vaccinex, Inc. – Pipeline By Molecule Type, 2011
Vaccinex, Inc. – Recent Pipeline Updates, 2011
Vaccinex, Inc., Deals Summary, 2004 to YTD 2011
Vaccinex, Inc., Deals Summary by Region, 2004 to YTD 2011
Vaccinex, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Vaccinex, Inc. – Pipeline by Therapy Area and Indication, 2011
Vaccinex, Inc. – Pipeline by Stage of Development, 2011
Vaccinex, Inc. – Monotherapy Products in Pipeline, 2011
Vaccinex, Inc. – Pipeline By Therapeutic Class, 2011
Vaccinex, Inc. - Pipeline By Target, 2011
Vaccinex, Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture - Profile - US
• Dell - Profile - US